Author Archives: admin


Stem cell scientists discover potential way to expand cells for use with patients

ScienceDaily (Nov. 8, 2012) Canadian and Italian stem cell researchers have discovered a new "master control gene" for human blood stem cells and found that manipulating its levels could potentially create a way to expand these cells for clinical use.

The findings, published today online ahead of print in Cell Stem Cell, usher in a new paradigm for the regulation of human blood stem cells, says co-principal investigator Dr. John Dick, who holds a Canada Research Chair in Stem Cell Biology and is a Senior Scientist at University Health Network's McEwen Centre for Regenerative Medicine and Ontario Cancer Institute (OCI), the research arm of the Princess Margaret Cancer Centre. He is also a Professor in the Department of Molecular Genetics, University of Toronto.

"For the first time in human blood stem cells, we have established that a new class of non-coding RNA called miRNA represents a new tactic for manipulating these cells, which opens the door to expanding them for therapeutic uses," says Dr. Dick.

In 2011, Dr. Dick isolated a human blood stem cell in its purest form -- as a single stem cell capable of regenerating the entire blood system -- paving the way for clinical uses. He also pioneered the cancer stem cell field by identifying leukemia stem cells in 1994 and colon cancer stem cells in 2007.

OCI lead author Dr. Eric Lechman says the research team removed a master control gene -- microRNA 126 (miR-126) -- that normally governs the expression of hundreds of other genes by keeping them silenced, which in turn keeps the stem cells in a non-dividing dormant state. The method was to introduce excess numbers of miR-126 binding sites into the stem cells by using a specially designed viral vector.

"The virus acted like a sponge and mopped up the specific miRNA in the cells. This enabled the expression of normally repressed genes to become prominent, after which we observed a long-term expansion of the blood stem cells without exhaustion or malignant transformation," says Dr. Lechman.

Adds Dr. Dick: "We've shown that if you remove the miRNA you can expand the stem cells while keeping their identity intact. That's the key to long-term stem cell expansion for use with patients." The co-principal investigator was Dr. Luigi Naldini, Director, of the San Raffaele Telethon Institute for Gene Therapy, Milan.

Dr. Dick's research was funded by the Canadian Institutes of Health Research, the Canadian Cancer Society, the Terry Fox Foundation, Genome Canada through the Ontario Genomics Institute, the Ontario Institute for Cancer Research, the Canada Research Chair Program, the Ontario Ministry of Health and Long-Term Care, the Canada Foundation of Innovation, as well as The Princess Margaret Cancer Foundation.

Share this story on Facebook, Twitter, and Google:

Other social bookmarking and sharing tools:

Read the original post:
Stem cell scientists discover potential way to expand cells for use with patients

Stem Cell Research Continues to Make Major Breakthroughs in 2012

NEW YORK, NY--(Marketwire - Nov 8, 2012) - Stem cell stocks have been gaining popularity among investors in 2012 as new and promising research continues to propel the industry forward. A study performed earlier this year at Johns Hopkins University has shown that stem cells from patients' own cardiac tissue can be used to heal scarred tissue after a heart attack. Five Star Equities examines the outlook for companies in the Biotechnology Industry and provides equity research on StemCells, Inc. ( NASDAQ : STEM ) and Neuralstem, Inc. ( NYSE : CUR ).

Access to the full company reports can be found at:

http://www.FiveStarEquities.com/STEM

http://www.FiveStarEquities.com/CUR

A more recent study, also conducted at Johns Hopkins University, has showed that stem cells donated by strangers were as safe and as effective as the patient's own cells in repairing heart tissue. This is a key advancement for the treatment of heart attack with stem cells, as this possibly means stem cells could be stored for use just as blood is now.

"You could have the cells ready to go in the blood bank so when the patient comes in for a therapy -- there's no delay," said Dr. Joshua Hare of the University of Miami. "It's also cheaper to make the donor cells," as marrow from a single donor could provide enough cells for the treatment of up to 10 people.

Five Star Equities releases regular market updates on the Biotechnology Industry so investors can stay ahead of the crowd and make the best investment decisions to maximize their returns. Take a few minutes to register with us free at http://www.FiveStarEquities.com and get exclusive access to our numerous stock reports and industry newsletters.

StemCells is applying its scientific and industry leadership in stem cell biology to discover, develop and commercialize breakthrough therapeutics and enabling tools and technologies for use in stem cell-based research and drug discovery. The company in October launched four new SC Proven human neural stem cell (NSC) kits for use in neuroscience research.

Different regions of the brain and spinal cord house different, specialized cells. Neuralstem's technology enables the isolation and expansion of human neural stem cells from each of these regions of the developing central nervous system (CNS) in virtually unlimited numbers from a single donated tissue.

Five Star Equities provides Market Research focused on equities that offer growth opportunities, value, and strong potential return. We strive to provide the most up-to-date market activities. We constantly create research reports and newsletters for our members. Five Star Equities has not been compensated by any of the above-mentioned companies. We act as an independent research portal and are aware that all investment entails inherent risks. Please view the full disclaimer at: http://www.FiveStarEquities.com/disclaimer

Visit link:
Stem Cell Research Continues to Make Major Breakthroughs in 2012

Stem Cell Stocks Gaining Popularity in 2012 as a Result of Breakthroughs in Research

NEW YORK, NY--(Marketwire - Nov 8, 2012) - Stem cell stocks have been gaining popularity among investors in 2012 as new and promising research continues to propel the industry forward. A study performed earlier this year at Johns Hopkins University has shown that stem cells from patients' own cardiac tissue can be used to heal scarred tissue after a heart attack. Five Star Equities examines the outlook for companies in the Biotechnology Industry and provides equity research on Cytori Therapeutics Inc. (USA) ( NASDAQ : CYTX ) and Pluristem Therapeutics Inc. ( NASDAQ : PSTI ).

Access to the full company reports can be found at:

http://www.FiveStarEquities.com/CYTX

http://www.FiveStarEquities.com/PSTI

A more recent study, also conducted at Johns Hopkins University, has showed that stem cells donated by strangers were as safe and as effective as the patient's own cells in repairing heart tissue. This is a key advancement for the treatment of heart attack with stem cells, as this possibly means stem cells could be stored for use just as blood is now.

"You could have the cells ready to go in the blood bank so when the patient comes in for a therapy -- there's no delay," said Dr. Joshua Hare of the University of Miami. "It's also cheaper to make the donor cells," as marrow from a single donor could provide enough cells for the treatment of up to 10 people.

Five Star Equities releases regular market updates on the Biotechnology Industry so investors can stay ahead of the crowd and make the best investment decisions to maximize their returns. Take a few minutes to register with us free at http://www.FiveStarEquities.com and get exclusive access to our numerous stock reports and industry newsletters.

Shares of Cytori Therapeutics have soared nearly 60 percent year-to-date. The company develops, manufactures, and sells medical products and devices to enable the practice of regenerative medicine. The Company's technology is the Celuion family of products, which processes patients' adipose-derived stem and regenerative cells (ADRCs) at the point of care.

Pluristem Therapeutics is a bio-therapeutics company engaged in the commercialization of non-personalized cell therapy products for the treatment of several severe degenerative, ischemic and autoimmune disorders. The company recently announced that their manufacturing facility in Israel reached a major milestone and that they have initiated the Installation Qualification validation.

Five Star Equities provides Market Research focused on equities that offer growth opportunities, value, and strong potential return. We strive to provide the most up-to-date market activities. We constantly create research reports and newsletters for our members. Five Star Equities has not been compensated by any of the above-mentioned companies. We act as an independent research portal and are aware that all investment entails inherent risks. Please view the full disclaimer at: http://www.FiveStarEquities.com/disclaimer

See more here:
Stem Cell Stocks Gaining Popularity in 2012 as a Result of Breakthroughs in Research

Lysosomal Storage Disorders – Video


Lysosomal Storage Disorders
ll4.me Lysosomal Storage Disorders From Lysosomes to Storage Diseases and Back: A Personal Reminiscence.- Lysosomal Biogenesis and Disease.- The Concept of Treatment in Lysosomal Storage Diseases.- Complex Lipid Catabolism.- Retroviral Vectors for Gene Therapy.- Adenovirus in Gene Therapy.- Setting Back the Clock: Adenoviral-Mediated Gene Therapy for Lysosomal Storage Disorders.- Adeno-Associated Viral-Mediated Gene Therapy of Lysosomal Storage Disorders.- Herpes Simplex Virus Vectors for Gene Therapy of Lysomal Storage Disorders.- Gene Therapy of Lysosomal Storage Disorders by Lentiviral Vectors.- Substrate Reduction Therapy.- Newborn Screening for Lysosomal Storage Disorders.- Genetic Counseling for Lysosomal Storage Diseases.- Neural Stem Cell Therapy in Lysosomal Storage Disorders.- The GM1 Gangliosidoses.- The GM2 Gangliosidoses.- Acid Sphingomyelinase-Deficient Niemann-Pick Disease.- Krabbe Disease (Globoid Cell Leukodystrophy).- Metachromatic Leukodystrophy.- Fabry Disease.- Gaucher Disease: Review and Perspectives on Treatment.- Therapeutic Goals in the Treatment of Gaucher Disease.- The Neuronal Ceroid Lipofuscinoses: Clinical Features and Molecular Basis of Disease.- Mucopolysaccharidosis I.- Mucopolysaccharidosis II.- Sanfilippo Syndrome: Clinical Genetic Diagnosis and Therapies.- Mucopolysaccharidosis IV (Morquio Syndrome; MPS IV).- Mucopolysaccharidosis Type VI (MPS VI, Maroteaux-Lamy Syndrome).- Mucopolysaccharidosis Type VII (Sly Disease): Clinical, Genetic ...From:davidbrown9865Views:0 0ratingsTime:00:13More inPeople Blogs

Go here to read the rest:
Lysosomal Storage Disorders - Video

The Patients of Angeles Health International – Video


The Patients of Angeles Health International
What our patients have to say about their experiences at Angeles Health International. All patients were treated for different conditions, in separate departments throughout our facilities. Angeles Health International offer cutting edge care, procedures and treatment in the following areas: Weight Loss Surgery - http://www.weightlossmex.com Stem Cell Therapy - http://www.stemcellmx.com Multiple Sclerosis Treatment - http://www.ccsvi.mx Effective Chemotherapy-free Cancer Treatment - http://www.cancertreatmentmx.com Visit the Angeles Health International website here: http://www.angeleshealth.com There are a team of healthcare professionals waiting to hear from you. Contact Angeles Health International toll free on: 1.866.668.9263From:AngelesHealthViews:5 0ratingsTime:03:06More inScience Technology

The rest is here:
The Patients of Angeles Health International - Video

Cardiac Cell Therapy Phase III Trial to Treat Refractory Angina

RIO DE JANEIRO--(BUSINESS WIRE)--

CryopraxisTM/CellPraxis aims to start patient recruitment for its Phase III Refractory Angina Cell Therapy Brazilian arm clinical trial by the end of 2012 or early 2013. The phase IIA/B clinical trial study was completed in December 2011. These trials involved the use of a proprietary autologous stem cell formulation (MonocellTM) indicated for neoangiogeneses.

Safety and efficacy of this product was evaluated in patients with refractory angina, a no option disease condition, characterized by severe chest pain for which there is no efficient treatment available, says the President of both Companies, Eduardo Cruz.

ReACT, MonocellTMs derived product, showed evidence of safety and efficacy in our initial clinical trials. All patients included in this trial were classified as Class IV Angina in CCSAC* (the most severe class of chest pain). In the first group of patients, whose data was published**, there was a progressive and sustained improvement in angina symptoms, with 87.5% of the patients completing the clinical trial with a CCSAC score of 0 or 1.

Angina symptom relief began as early as 3 months post procedure with continuing improvement through the 18th month, suggesting that angiogenesis began early, and that it kept evolving 18 months after the procedure. Objective evaluation of stress myocardium perfusion (scintigraphic analysis), after 1 year of follow-up, gave indications of complete myocardial reperfusion in 75% of the patients, says Dr. Nelson Hossne, Medical Director of CellPraxis. Our conclusion was ReACT's specific cell formulation, MonoCell, had a direct correlation to myocardial neoangiogeneses.

About CryopraxisTM (www.cryopraxis.com.br) and CellPraxis (www.cellpraxis.com)

Located at Bio-Rio Biotech Cluster (Rio de Janeiro, Brazil), CryopraxisTM is the pioneer and the largest bank of umbilical cord blood in Brazil and has been in operation since 2001, with approximately 25,000 customers. CellPraxis is a bioengineering company that invests in research projects involving stem cell therapy. Some of these projects are conducted in partnership with institutions like the Federal University of Rio de Janeiro, Federal University of So Paulo, the University of South Florida and Saneron CCEL Therapeutics, Inc. (a USA based biotechnology company dedicated to stem cell research).

Forward-Looking Statement

This press release contains forward-looking statements within the meaning of the Private Securities Litigation Reform Act of 1995. Forward-looking statements reflect management's current expectations, as of the date of this press release, and involve certain risks and uncertainties. The Company's actual results could differ materially from those anticipated in these forward- looking statements as a result of various factors. The Company's further development is highly dependent on future medical and research developments and market acceptance, which is outside its control.

See the original post:
Cardiac Cell Therapy Phase III Trial to Treat Refractory Angina

Spinal Cord Injury D10 Level Before and After Stem Cell Treatment – Video


Spinal Cord Injury D10 Level Before and After Stem Cell Treatment
Stem Cell Treatment done at Neurogen ,Brain Spine Institute, Surana Sethia Hospital and Research Centre, Suman Nagar, Sion-Trombay Road, Chembur,Mumbai-71. Website -- http://www.neurogen.in http://www.stemcellsmumbai.com Tel: - +91 9920 200400, 022-25283706From:neurogenbsiViews:7 1ratingsTime:01:23More inScience Technology

Read the rest here:
Spinal Cord Injury D10 Level Before and After Stem Cell Treatment - Video